Learn how long you'll likely receive Keytruda infusions, what factors can affect your treatment length, and what to expect ...

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo ...

The FDA approval is based on the results of the open-label KEYNOTE-224 trial ... Overall, the results with Keytruda are very similar to that seen with BMS’ PD-1 inhibitor Opdivo (nivolumab ...

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...

Keytruda's label does not require treatment to be stopped after two years and the number of patients receiving treatment after two years remains small, NICE noted in its guidance. Longer term ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Thanks in part to the label expansions for Keytruda, its sales grew by 18.6% year-on-year. Also, to support Merck's stock price, its management has allocated an additional $10 billion to a share ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

We look forward to working with the FDA to potentially bring KEYTRUDA to these patients as soon as possible.” The randomized, active-controlled, open-label KEYNOTE-689 trial evaluated Keytruda as both ...

There also appears to be growing regulatory apprehension regarding the widespread use of Keytruda—and PD-1 inhibitors more broadly. In September 2024, an FDA advisory panel overwhelmingly voted to ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...